You might also like
Cardio Diagnostics Holdings, Inc. (CDIO) is a precision cardiovascular medicine company that develops and commercializes epigenetic-based clinical tests and services. The company leverages its proprietary AI-driven Genetic-Epigenetic Engine platform to improve the prevention, detection, and management of cardiovascular diseases. CDIO offers clinical tests, a SaaS product, and is actively expanding its product portfolio to address additional health conditions.
- PrecisionCHD™ and Epi+Gen CHD™ Tests - Provide epigenetic-based solutions for the detection and management of coronary heart disease, supported by Medicare pricing and CPT PLA codes.
- HeartRisk SaaS Product - Offers a software-as-a-service platform to enhance adoption across health systems and self-insured employers.
- Pipeline Development - Focuses on creating new clinical tests for stroke, congestive heart failure, and diabetes to expand its offerings.
- Telemedicine and Provider Services - Delivers its products through telemedicine platforms and partnerships with provider organizations across multiple states.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Meeshanthini (Meesha) V. Dogan ExecutiveBoard | Chief Executive Officer | CEO and Director at Cardio Diagnostics Holdings, Inc. since its inception in 2017, with extensive experience in biomedical and chemical engineering, pioneering AI-driven cardiovascular diagnostics. | View Report → | |
Robert (Rob) Philibert ExecutiveBoard | Chief Medical Officer | Robert (Rob) Philibert, MD PhD, has served as Chief Medical Officer and Director at CDIO since its inception; he is also a co-founder of Legacy Cardio. | ||
Elisa Luqman Executive | Chief Financial Officer (CFO) | Elisa Luqman has served as the Chief Financial Officer at CDIO since March 2021, focusing on financial and compliance responsibilities with no board or committee memberships. | ||
Timur Dogan Executive | Chief Technology Officer (CTO) | Timur Dogan is the Chief Technology Officer (CTO) at CDIO since May 2022. He previously served as a Senior Data Scientist at Legacy Cardio starting in August 2019. | ||
James Intrater Board | director | President at IntraMont Technologies since June 2014; Engineering consultant at Falcon AI since May 2020 | James Intrater has served as a director at CDIO since October 2022. He brings extensive experience in healthcare product development and federal R&D, exemplified by his concurrent roles as President of IntraMont Technologies since June 2014 and as an engineering consultant for Falcon AI since May 2020. | |
Paul F. Burton Board | Member of the Board of Directors | Managing Partner at 2Flo Ventures; Chief Executive Officer of Akan Biosciences; Chief Financial Officer of Temprian Therapeutics | Paul F. Burton has served as a member of the Board of Directors at CDIO since December 2023. He brings extensive expertise in corporate finance and early-stage healthcare while holding additional active roles outside CDIO. | |
Peter K. Fung Board | Member of the Board of Directors | Director of Cardiovascular Division at Beverly Hospital since 2004 ; Director of Research and Education at Central California Heart Institute since 1992 ; Director of Nuclear Cardiology at Central Cardiology Medical Clinic since 1991 | Peter K. Fung, M.D. has been serving as a member of the Board of Directors at CDIO since November 15, 2024. He also serves on the nominating and corporate governance committee and the compensation committee. | |
Warren Hosseinion Board | Non-Executive Chairman of the Board | President and Director at Nutex Health, Inc. since April 2022; Board Member at Astrana Health, Inc. since July 2008 | Warren Hosseinion, M.D. has been serving as the Non-Executive Chairman of the Board at CDIO since October 2022. He previously held roles at Legacy Cardio and has extensive experience in healthcare leadership, including active positions at Nutex Health and Astrana Health. | |
Wendy J. Betts Board | Member of the Board of Directors | Information Security Officer at Rotary International ; Director at Luminarts Culture Foundation | Wendy J. Betts serves as an independent director at CDIO since November 15, 2024. She also actively chairs the Nominating and Corporate Governance Committee and serves on the Audit Committee, leveraging her extensive background in cybersecurity and risk management. |
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
Cleerly | We face competition from various sources, including large, well-capitalized technology companies such as this one. These competitors may have better brand name recognition, greater financial and engineering resources and larger sales teams than we have. As a result, our competitors may be able to develop and introduce competing solutions and technologies that may have greater capabilities than our solutions or that are able to achieve greater customer acceptance, and they may be able to respond more quickly and effectively than we can to new or changing opportunities, technologies, standards or customer requirements. |
Prevencio | Proteomic methods, as exemplified by serologic assessments of individual proteins such as c-reactive protein or of entire protein panels, such as that for the HART CADhs or CVE tests from this company are another risk assessment tool. The CADhs test is a good example of a proteomic competitor and predicts the one-year risk for having ≥70% stenosis in a major coronary artery while another test HART CVE, predicts one year risk for individuals at risk for developing a major adverse cardiovascular event. |
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
Cardio Diagnostics, Inc. | 2022 | Deal Structure: Acquired via a definitive business combination agreement with Mana Capital Acquisition Corp. (a SPAC) on May 27, 2022, resulting in its public listing as Cardio Diagnostics Holdings, Inc. with ticker symbols CDIO and CDIOW. Strategic Rationale & Key Capabilities: The acquisition advances precision cardiovascular medicine by leveraging its proprietary Integrated Genetic-Epigenetic Engine™ and flagship product Epi+Gen CHD™, targeting a $51 billion total addressable market. Terms: Included extension payments of $216,667 to extend the SPAC’s timeline, ensuring sufficient cash on hand to fund operations through 2023. |
No recent press releases or 8-K filings found for CDIO.